Zydus starts phase II trial of ZYAN1 for treating anemia in patients with CKD

Zydus today announced the initiation of a phase II trial investigating ZYAN1, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a treatment for anemia associated with chronic kidney disease.

July 05, 2017 / 11:44 AM IST

live

bselive
nselive

Volume

Todays L/H

Zydus starts phase II trial of ZYAN1 for treating anemia in patients with CKD.Source : BSE

Tags: #Announcements

first published: Jul 5, 2017 11:44 am

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Invest in Commercial Real Estate Fractionally

Expert Trading Guidance

Countdown to Lok Sabha Elections 2024

Zydus starts phase II trial of ZYAN1 for treating anemia in patients with CKD

Zydus today announced the initiation of a phase II trial investigating ZYAN1, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a treatment for anemia associated with chronic kidney disease.